The 3rd mRNA Process Development & Manufacturing Summit 2025 returns as Europe’s premier industry-focused forum, dedicated to optimizing process development for mRNA therapeutics and vaccines. This event will address end-to-end process optimisation, regulatory compliance to streamline approvals, while also advancing scalable and cost-efficient manufacturing solutions, to support drug developers in delivering safer and more effective mRNA drugs […]

The 2nd ADC Payload Summit (May 6-8 | Boston, MA) is the first and only conference exclusively focusing on ADC payloads, helping you to reimagine the medicinal chemistry of traditional cytotoxic payloads while scouting the next generation of ADC payload innovations. With novel payload categories such as degraders, RNA polymerase II inhibitors, immunomodulators, gene silences, […]

The ALS Drug Development Summit is the definitive industry-led forum dedicated to advancing breakthroughs in ALS therapeutics. With the field evolving rapidly, recent milestones—such as Insitro’s AI-driven target discovery with Bristol Myers Squibb and Dewpoint Therapeutics’ collaboration with Mitsubishi Tanabe Pharma America on TDP-43 condensate modulators—highlight the momentum in novel drug discovery. Meanwhile, QurAlis’ clinical […]

Following a year of exceptional progress in IBD drug development, fierce competition in clinical trials for Chron’s Disease and Ulcerative Colitis remains high, and it’s time for biopharma to push the boundaries of efficacy and distinguish their therapies amongst the market. Featuring three days of data-driven sessions from 25+ world-class speakers, the 3rd Precision Medicine […]

From molecular glue discovery to the development of degrader-antibody conjugates, pharma is transforming through strategic transactions and by leveraging protein degradation technologies to expand target discovery and drug previously 'undruggable' targets. This provides biotech with the opportunity to understand pharma's targets of interest and the options for increased specificity and selectivity compared to traditional molecules. […]

The 4th GPCR-Targeted Drug Discovery Summit: Transforming the Discovery of Novel GPCR-Targeted Therapies. With positive clinical read outs by Tectonic Therapeutics and recent funding rounds for Confo Therapeutics & Septerna, the potential for novel GPCR drug classes to treat a plethora of diseases grows. Now more than ever, there is a need for the community […]

The 6th Gene Therapy Analytical Development Summit Europe is the leading platform for advancing gene therapy analytics, from IND/IMPD filings to clinical trials and regulatory approvals. As the field moves toward late-stage development, gain industry-focused insights tailored for Europe. Join 24+ experts to tackle characterisation, stability, contamination risks, and comparability across vectors and diseases. Network with biotech, pharma, MHRA, and British Pharmacopoeia to share solutions and shape the future […]

The 3rd Retinal Imaging Biomarkers & Endpoints Summit will bring together leading experts spanning medical directors, researchers, clinical, and imaging scientists from more than 30 organizations spearheading ophthalmic development with deep learning systems and sophisticated AI imaging technologies. It’s here they will explore the latest advancements in retinal imaging, biomarkers, and endpoints for ophthalmic drug […]

Current limitations across pricing, coverage, and payment frameworks are lasering out and hindering global access to many approved cell and gene therapies (CGTs). The Cell & Gene Therapy Pricing & Reimbursement Summit is here to change that. Returning for its 2nd edition, this unique summit will share real-world case studies of success and setback in […]

Join the 4th Circular & Self-Amplifying RNA Therapeutics Summit! Unleashing the Next Generation of RNAs for Widespread Therapeutic Applications With CSL Seqirus and Arcturus Therapeutics successfully developing the first approved self-amplifying RNA vaccine, the field of next generation RNAs celebrates the potential of circular and self-amplifying RNAs to provide improved stability, durability, longevity and efficacy […]

Accelerating the Route to Commercialization with Robust Potency Assay Development Following a challenging year in the gene therapy field, the 3rd Gene Therapy Potency Assay Summit returns at a crucial time when drug developers increasingly recognize that a robust potency assay is fundamental to both clinical success and commercial viability. As regulatory expectations continue to evolve, it has never […]